NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Given Consensus Recommendation of “Buy” by Brokerages

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) has been assigned an average recommendation of “Buy” from the five analysts that are covering the firm, Marketbeat.com reports. Four investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $28.50.

NRXP has been the topic of a number of recent research reports. BTIG Research restated a “buy” rating on shares of NRx Pharmaceuticals in a research note on Monday, August 25th. Wall Street Zen upgraded shares of NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, May 22nd. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $31.00 target price on shares of NRx Pharmaceuticals in a report on Tuesday, August 19th.

NRx Pharmaceuticals Stock Performance

NASDAQ NRXP opened at $2.60 on Friday. The firm has a market cap of $51.51 million, a PE ratio of -1.16 and a beta of 1.63. NRx Pharmaceuticals has a one year low of $1.10 and a one year high of $6.01. The firm’s fifty day moving average is $2.86 and its two-hundred day moving average is $2.54.

NRx Pharmaceuticals (NASDAQ:NRXP) last posted its quarterly earnings data on Monday, August 18th. The company reported ($0.98) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.67). Research analysts predict that NRx Pharmaceuticals will post -1.75 earnings per share for the current year.

Institutional Trading of NRx Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Squarepoint Ops LLC purchased a new stake in shares of NRx Pharmaceuticals in the fourth quarter valued at about $56,000. Millennium Management LLC purchased a new stake in shares of NRx Pharmaceuticals in the fourth quarter valued at about $61,000. Anson Funds Management LP boosted its holdings in shares of NRx Pharmaceuticals by 535.1% in the first quarter. Anson Funds Management LP now owns 1,179,061 shares of the company’s stock valued at $2,417,000 after acquiring an additional 993,401 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of NRx Pharmaceuticals by 27.9% in the second quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock valued at $562,000 after acquiring an additional 37,598 shares in the last quarter. Hedge funds and other institutional investors own 4.27% of the company’s stock.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.